Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared on LinkedIn, adding:
”Today is Rare Disease Day.
I work actively in the field of rare diseases, where progress often depends on rigorous research, multidisciplinary collaboration, and responsible clinical decision-making.
This image captures a milestone in our clinical practice: in September 2024, we administered the first gene therapy for Hemophilia A in our center.
Innovation in rare diseases is never abstract.
It is built carefully, through evidence, integrity, and high standards especially when patient numbers are small and every decision carries weight.
Raising awareness matters.
Building reliable evidence matters even more.
In rare diseases, small numbers require higher standards not lower ones.”
Stay updated with Hemostasis Today.
-
Nov 3, 2026, 22:00Ravi C Dara: What’s New in ASFA’s 10th Edition – Practical Updates for the Apheresis Clinician
-
Nov 3, 2026, 21:46Cedric Hermans: Treatment Differentiators for Shared Decision-Making in Haemophilia in 2026
-
Nov 3, 2026, 21:38Arwa Z. Al-Riyami: AI Opportunities and Future Directions in Transfusion Medicine
-
Nov 3, 2026, 21:11Yazan Abou-Ismail: Presenting at American College of Emergency Physicians and MWTCC in the Same Week
-
Nov 3, 2026, 21:05Anirban Sen Gupta: Escalating-Dose Lyophilized SynthoPlate for Emergency Trauma Mitigation
-
Nov 3, 2026, 20:50Mostafa Faisal Mohammed Saleh: Targeting Plasma Cells to Control Persistent ADAMTS13 Autoantibodies in iTTP
-
Nov 3, 2026, 16:57Ahmed Alotaibi: Which Macrophage Receptor ‘eats’ anti-E and Anti-K Coated RBCs?
-
Nov 3, 2026, 16:53Jan Sloves: Key Factors for Achieving Durable Patency in Advanced Venous Stenting
-
Nov 3, 2026, 16:45Nina Weber: Review on Kidney Injury After Stem Cell Transplantation